Replies to post #396526 on NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

That’s kind of like how Rindopepimut’s phase III trial played out.

First there was the announcement that they were discontinuing the trial on March 6, 2016.
https://ir.celldex.com/news-releases/news-release-details/data-safety-and-monitoring-board-recommends-celldexs-phase-3

And then in October 2017 (20 months later on a brisk Fall day), the detailed publication was released.
https://pubmed.ncbi.nlm.nih.gov/28844499/

[Lykiri]

fun fact NWBO, the initiator of the publication, is not the investigator Dr Liau is.
So if the trial would have failed she would no doubt publish about it in 3 or 4 years from now on a sunny Sunday afternoon. This has happened over and over with other trials

anders2211,

I don't think that's right, unless Linda Liau has changed her mind since June 3, 2021. (UCSF- Resident Research Day Lecture)

Resident Research Day Guest Speaker: Dr. Linda Liau
Professor and W. Eugene Stern Chair, Neurosurgery Department
Director, UCLA Brain Tumor SPORE
David Geffen School of Medicine at UCLA
"Immunotherapy in Brain Tumors: New Concepts"